A Child and Adolescent Psychiatrist’s Perspective on Youth Mental Health Care—Some Timely Topics for Reform
by Terry Lee, M.D.
With 16% of the United States GDP going towards health care, health care reform is one of the top domestic priorities of the Obama administration and Congress. In its recent health care and the federal budget report, the Congressional Budget Office (CBO) estimated that health care overhaul, including universal coverage, will cost approximately $1 trillion over the next 10 years. The report goes on to discuss potential savings that may help pay for increased coverage, noting: “Significant savings seem possible because the available evidence implies that a substantial share of spending on health care contributes little if anything to the overall health of the nation. Therefore, experts generally agree that changes in government policy have the potential to produce substantial savings in both national and federal spending on health care without harming health.”
What will reform in the youth mental health care system look like? The National Research Council and Institute of Medicine recently estimated that the total economic cost of mental, emotional and behavioral disorders of Americans under the age of 25 was $247 billion in 2007. How can the youth mental health system be more effective and efficient?
Increasing coverage for child psychiatric services will not immediately remedy access problems. There is a national shortage of child and adolescent psychiatrists. It was previously estimated that the United States would need more than 30,000 child and adolescent psychiatrists by the year 2000.1 However, there were approximately 6300 child psychiatrists in the United States in 2000.2 The severe national shortage of child psychiatrists is further heightened in Washington State. Using 2001 data, the Washington State rate of child psychiatrists per 100,000 youth was calculated to be 6.6, which was below the national rate of 8.67.3 Other psychiatric prescribers, such as nurse practitioners, physician assistants and primary care providers, are already important members of the youth mental health system, and are critical for increasing treatment capacity.
With increased access, treatments will need to be effective. Why increase access just to waste resources on treatments that don’t work? For instance, in a 1999 randomized-controlled study of traditional child psychotherapy, youth in the treatment group were prescribed psychotherapy by practicing therapists, while the control group received academic tutoring.4 The treatment group received an average of 60 individual sessions, 4 group therapy sessions, 18 parent sessions, 13 school personnel consultations and 1 session of psychiatry consultation. In spite of this large and costly dose of psychotherapeutic intervention, outcomes for the treatment group were no better than the control group. The entire system should not be impugned based on a single study from 1999, but in child mental health and medicine in general, doing something is not always better than doing nothing. There is plenty of room for the development of effective and accessible treatments. Fortunately, there have been some favorable advances in the development and dissemination of effective treatments for youth and families in real world settings over the last 10 years.
One exciting area of progress are meta-analyses and longer-term studies examining psychosocial interventions, psychotropic medications, and their relative and combined effects for problems such as attention-deficit/hyperactivity disorder5,6 depression7,8 and anxiety.9 So for a given problem, youth and families are better informed of the relative pros and cons of combined psycho- and pharmacotherapy, compared to the individual components alone. Considerations such the availability of empirically-based psychotherapies and personal preferences about medication will also affect choice, but youth and families have a much better idea of the likeliest outcomes of the various treatment options.
Appropriate use of psychiatric medications will also improve efficiencies in the child health care system. Used properly for the problems they have been demonstrated to help with, psychiatric medications are valuable tools in the youth mental health system. Stimulant medications for the treatment of ADHD are relatively well-supported in the literature. More recently, there has been an explosion in the use of second-generation antipsychotic medications in youth for all sorts of problems unrelated to psychosis. Antipsychotic medications are now being prescribed for disruptive behavior and mood regulation problems, even though there is no proven long-term effectiveness or safety for youth with these problems.
The diagnosis of bipolar disorder remains a controversial area in child psychiatry. Between 1994-5 and 2002-3, there was a forty-fold increase in the diagnosis of bipolar disorder in patients under the age of 20 in the United States.10 The same study found an almost doubling of the rate of diagnosis of bipolar disorder in adults aged 20 and older. Is the incidence of bipolar disorder in youth going up? Not so clearly outside of the United States. European countries have not reported anywhere near the incidence nor increase of diagnosis of pediatric bipolar disorder as the United States.11 For instance, a large epidemiological study in the United Kingdom found 0 cases of pre-adolescent mania and 0 cases of bipolar disorder among 2500 youth less than 10-years-old over a ten year time period.12 Time, and further research, will tell whether there is a true increase in the incidence of youth bipolar disorder; but currently, the evidence is lacking.
There is no doubt that the youth in this country diagnosed with bipolar disorder have very serious behavioral and mental health challenges. It’s just not clear at this time how a diagnosis of bipolar disorder helps these youth and families. To get a flavor of the pediatric bipolar controversy, see the compelling January 2008 Frontline episode at http://www.pbs.org/wgbh/pages/frontline/shows/medicating/
Recently, there’s been some convergence in the thinking around pediatric bipolar disorder and the use of medications. At the recent FDA Psychopharmacologic Drugs Advisory Committee review of requests for approval of three second-generation antipsychotics for the treatment of schizophrenia and/or bipolar disorder in pediatric populations, American Academy of Child and Adolescent Psychiatry (AACAP) President-Elect Laurence Greenhill, urged caution and suggested and further long-term studies to evaluate long-term safety and efficacy, including require a central national registry. The committee was very concerned about the incidence and seriousness of side effects associated with the medications. In the end, the committee recommended approval for use in pediatric populations; and additionally recommended labels clarifying use of these medications for narrowly-defined bipolar disorder and schizophrenia, and not for use in severe mood regulation, chronic irritability, oppositional behavior or hyperactivity.
These are just some topics that come to mind when I think of youth mental health care reform. What do you think?
____________________________________________________
1 Council on Graduate Medical Education. Re-examination of the Academy of Physician Supply made in 1980 by the Graduate Medical Education National Advisory Committee for selected specialties, Bureau of Health Professions in support of activities of the Council on Graduate Medical Education. 1990. Cambridge, ABT Associates.
2 Kim WJ, American Academy of Child and Adolescent Psychiatry Task Force on Workforce Needs. (2003). Child and adolescent psychiatry workforce: a critical shortage and national challenge. Academic Psychiatry, 27, 277-82.
3 Thomas CR, Holzer CE. The continuing shortage of child and adolescent psychiatrists. Journal of the American Academy of Child and Adolescent Psychiatry, 2006; 45, 1023-1031.
4 Weiss B, Catron T, Harris V, Phung TM. The effectiveness of traditional child psychotherapy. Journal of Consulting and Clinical Psychology, 1999; 67: 82-94.
5 The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 1999; 56:1073-1086.
6 Van der Oord S, Prins PJM, Oosterlaan J, Emmelkamp PMG. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev. 2008; 28: 783-800.
7 March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty, S Vitiello B, Severe J. The treatment for adolescents with depression study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007; 64: 1132-43.
8 Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, While L, Harrington R. A randomized controlled trial of cognitive behavior therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess. 2008; 12: iii-iv, ix-60.
9 Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008; 359: 2753-66.
10 Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007; 64:1032-9.
11 Soutullo CA, Chang KD, Diez-Suarez A, Figueroa-Quintana A, Escamilla-Canales I, Rapado-Castro M, Ortuno F. Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology. Bipolar Disord. 2005; 7: 497-506.
12 Meltzer H, Gatward R, Goodman R, Ford T. Mental heal of children and adolescents in Great Britain. London, UK: Stationery Office, 2000.